Skin autofluorescence is associated with carotid intima-media thickness, diabetic microangiopathy, and long-lasting metabolic control in type 1 diabetic patients. Results from Poznan Prospective Study

Microvascular Research

Volumn 98, Issue , 2015, Pages 62-67

  Araszkiewicz, Aleksandra ^a   Naskret, Dariusz ^a   Zozulinska Ziolkiewicz, Dorota ^a   Pilacinski, Stanislaw ^a   Uruska, Aleksandra ^a   Grzelka, Agata ^a   Wegner, Malgorzata ^a   Wierusz Wysocka, Bogna ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Advanced glycation end products; Intima media thickness; Microangiopathy; Skin autofluorescence; Type 1 diabetes

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; HEMOGLOBIN A1C;

ADULT; AGE; ARTERIAL WALL THICKNESS; ARTICLE; BIOACCUMULATION; COHORT ANALYSIS; CONTROLLED STUDY; CUTANEOUS PARAMETERS; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE DURATION; FEMALE; GLYCEMIC CONTROL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELIABILITY; SKIN AUTOFLUORESCENCE; BLOOD PRESSURE; DIABETIC ANGIOPATHY; FLUORESCENCE MICROSCOPY; METABOLISM; MICROCIRCULATION; PATHOLOGY; RISK FACTOR; SKIN; YOUNG ADULT;

ADULT; BLOOD PRESSURE; CAROTID INTIMA-MEDIA THICKNESS; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MALE; MICROCIRCULATION; MICROSCOPY, FLUORESCENCE; PROSPECTIVE STUDIES; RISK FACTORS; SKIN; YOUNG ADULT;

EID: 84924918987     PISSN: 00262862     EISSN: 10959319     Source Type: Journal    
DOI: 10.1016/j.mvr.2015.01.002     Document Type: Article

References (35)

1. Araszkiewicz A., Zozulinska-Ziolkiewicz D., Trepinska M., et al. Knowledge after five-day teaching program in intensive insulin therapy performed at the onset of type 1 diabetes influence the development of late diabetic complications. Diabetes Res. Clin. Pract. 2008, 81:61-67.
2. Araszkiewicz A., Zozulinska-Ziolkiewicz D., Pilacinski S., et al. Baseline diabetic knowledge after 5-day teaching program is an independent predictor of subclinical macroangiopathy in patients with type 1 diabetes (Poznan Prospective Study). Adv. Med. Sci. 2014, 59:240-244.
3. Aroda V.R., Conway B.N., Fernandez S.J., et al. Cross-sectional evaluation of noninvasively detected skin intrinsic fluorescence and mean hemoglobin a1c in type 1 diabetes. Diabetes Technol. Ther. 2013, 15:117-123.
4. Bos D.C., de Ranitz-Greven W.L., de Valk H.W. Advanced glycation end products, measured as skin autofluorescence and diabetes complications: a systematic review. Diabetes Technol. Ther. 2011, 13:773-779.
5. Bucala R., Vlassara H. Advanced glycosylation end products in diabetic renal and vascular disease. Am. J. Kidney Dis. 1995, 26:875-888.
6. Chabroux S., Poitrine-Canoui F., Reffet S., et al. Advanced glycation end products assessed by skin autofluorescence in type 1 diabetics are associated with nephropathy, but not retinopathy. Diabetes Metab. 2010, 36:152-157.
7. Chawla D., Bansal S., Banerjee B.D., et al. Role of advanced glycation end product (AGE)-induced receptor (RAGE) expression in diabetic vascular complications. Microvasc. Res. 2014, 10.1016/j.mvr.2014.06.010.
8. Cleary P.A., Braffett B.H., Orchard T., et al. Clinical and technical factors associated with skin intrinsic fluorescence in subjects with type 1 diabetes from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. Diabetes Technol. Ther. 2013, 15:466-474.
9. Conway B.N., Aroda V.R., Maynard J.D., et al. Skin intrinsic fluorescence correlates with autonomic and distal symmetrical polyneuropathy in individuals with type 1 diabetes. Diabetes Care 2011, 34:1000-1005.
10. Den Dekker M.A., Zwiers M., van den Heuvel E.R., et al. Skin autofluorescence, a non-invasive marker for AGE accumulation, is associated with the degree of atherosclerosis. PLoS ONE 2013, 8(12):e83084.
11. Dorrian C.A., Cathcart S., Clausen J., et al. Factors in human serum interfere with the measurement of advanced glycation endproducts. Cell. Mol. Biol. 1998, 44:1069-1079.
12. Dyer D.G., Dunn J.A., Thorpe S.R. Accumulation of Maillard reaction products in skin collagen in diabetes and aging. J. Clin. Invest. 1993, 91:2463-2469.
13. Goh S.Y., Cooper M.E. The role of advanced glycation end products in progression and complications of diabetes. J. Clin. Endocrinol. Metab. 2008, 93:1143-1152.
14. KDOQI Clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am. J. Kidney Dis. 2007, 49(Suppl. 2):S12-S154.
15. Lutgers H.L., Gerrits E.G., Graaff R., et al. Skin autofluorescence provides additional information to the UK Prospective Diabetes Study (UKPDS) risk score for the estimation of cardiovascular prognosis in type 2 diabetes mellitus. Diabetologia 2009, 52:789-797.
16. Lutgers H.L., Graaff R., de Vries R., et al. Carotid artery intima media thickness associates with skin autofluorescence in non-diabetic subjects without clinically manifest cardiovascular disease. Eur. J. Clin. Invest. 2010, 40:812-817.
17. Meerwaldt R., Graaff R., Oomen P.H., et al. Simple non-invasive assessment of advanced glycation end product accumulation. Diabetologia 2004, 47:1324-1330.
18. Meerwaldt R., Lutgers H.L., Links T.P., et al. Skin autofluorescence is a strong predictor of cardiac mortality in diabetes. Diabetes Care 2007, 30:107-112.
19. Monnier V.M., Bautista O., Kenny D., et al. Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes. Diabetes 1999, 48:870-880.
20. Orchard T.J., Olson J.C., Erbey J.R., et al. Insulin resistance-related factors, but not glycemia, predict coronary artery disease in type 1 diabetes: 10-year follow-up data from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care 2003, 26:1374-1379.
21. Park L., Raman K.G., Lee K.J., et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat. Med. 1998, 4:1025-1031.
22. Quagliaro L., Piconi L., Assaloni R., et al. Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells. The role protein kinase C and NAD(P)H oxidase activation. Diabetes 2003, 52:2795-2804.
23. Reis J.S., Veloso C.A., Volpe C.M., et al. Soluble RAGE and malondialdehyde in type 1 diabetes patients without chronic complications during the course of the disease. Diabetes Vasc. Dis. Res. 2012, 9:309-314.
24. Ryle C., Donaghy M. Non-enzymatic glycation of peripheral nerve proteins in human diabetics. J. Neurol. Sci. 1995, 129:62-68.
25. Sakata N., Meng J., Jimi S., Takebayashi S. Nonenzymatic glycation and extractability of collagen in human atherosclerotic plaques. Atherosclerosis 1995, 116:63-75.
26. Samborski P., Naskret D., Araszkiewicz A., et al. Assessment of skin autofluorescence as a marker of advanced glycation end product accumulation in type 1 diabetes. Pol. Arch. Med. Sci. 2011, 121:67-72.
27. Skrha J., Soupal J., Loni Ekali G., et al. Skin autofluorescence relates to soluble receptor for advanced glycation end-products and albuminuria in diabetes mellitus. J. Diabetes Res. 2013, 2013:650694.
28. Sugisawa E., Miura J., Iwamoto Y., Uchigata Y. Skin autofluorescence reflects integration of past long-term glycemic control in patients with type 1 diabetes. Diabetes Care 2013, 36:2339-2345.
29. Tan K.C., Shiu S.W., Chow W.S., et al. Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes. Diabetologia 2006, 49:2756-2762.
30. The EDIC Research Group Effect of intensive diabetes treatment on carotid artery wall thickness in the epidemiology of diabetes interventions and complications. Diabetes 1999, 48:383-390.
31. Thomas M.C., Soderlund J., Lehto M., FinnDiane Study Group, et al. Soluble receptor for AGE (RAGE) is a novel independent predictor of all-cause and cardiovascular mortality in type 1 diabetes. Diabetologia 2011, 54:2669-2677.
32. Turk Z., Ljubic S., Turk N., Benko B. Detection of autoantibodies against advanced glycation endproducts and AGE-immune complexes in serum of patients with diabetes mellitus. Clin. Chim. Acta 2001, 303:105-115.
33. Uruska A., Araszkiewicz A., Uruski P., et al. Higher risk of microvascular complications in smokers with type 1 diabetes despite intensive insulin therapy. Microvasc. Res. 2014, 92:79-84.
34. Wautier J.L., Zoukourian C., Chappey O., et al. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J. Clin. Invest. 1996, 97:238-243.
35. Wilkinson C.P., Ferris F.L., Klein R.E., Global Diabetic Retinopathy Project Group, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 2003, 110:1677-1682.